Chronic mTOR hyperactivation drives ovarian aging through suppressed autophagy, mitochondrial dysfunction, impaired proteostasis, and oxidative stress in oocytes and cumulus cells — accelerating sharply after age 34. In a hybrid review-plus-docking study, pentadecanoic acid (C15:0), an odd-chain saturated fatty acid, was computationally evaluated against the mTOR kinase domain (PDB: 4JSV). It achieved a binding energy of -4.4 kcal/mol via hydrophobic contacts with Leu1936, Ile1939, Tyr2144, Val2227, and Gly2142 — weaker than rapamycin's -10.1 kcal/mol but mechanistically plausible through complementary AMPK activation and PPARα/δ modulation.
The finding lands at a genuinely underserved clinical intersection: mTOR inhibition improves oocyte quality and IVF outcomes in animal models, yet rapamycin's teratogenicity, immunosuppression, and lengthy pre-conception washout make it a non-starter for fertility patients. C15:0 sidesteps these concerns — it is endogenously produced, detectable in dairy fat, and has an emerging safety profile from Nils Burdock's longevity research. However, the limitations here are substantial. Molecular docking is hypothesis generation, not validation; the -4.4 kcal/mol affinity is modest and the biological relevance of in silico binding requires cell and animal confirmation. No human reproductive outcomes data exist. This is incremental but directionally important — C15:0 joins metformin and urolithin A as candidate metabolic modulators worth rigorous testing in ovarian aging models.